Kidney Cancer Association Applauds UK Drug Approval

   Change of Tack Shows Policy Shift and Saves LivesEvanston, IL, February 5, 2009– The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients. “This decision demonstrates the power of a unified voice,” said William Bro, president of the Kidney Cancer Association. “Patient advocates won’t sit back and watch decisions be made about their loved ones lives based on cost, not science. This drug and the three others still being reviewed are proven to be effective and we are delighted that thousands of deserving patients in the U.K. finally have access to life-saving drugs.” The drug, sunitinib (Sutent) is a novel, oral treatment that shows overall survival greater than two years in advanced kidney cancer patients. In September 2008, NICE advised against the use of Sutent and three other drugs (Avastin, Nexavar and Torisel). The decision reflects a change in policy guidelines that give greater consideration to the value that society places on end-of-life treatments. “The risk you run with a single payer system such as the on...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2–4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hippel-Lindau inactivation. Hypoxia-induced factor accumulation leads to transactivation of molecules involved in angiogenesis including vascular endothelial growth factor (VEGF) and platelet-derived growth factor. Sunitinib is an oral tyrosine kinase inhibitor that interacts with several angiogenesis recep...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CASE REPORTS Source Type: research
In this study, we sought to determine if the expression of receptor tyrosine kinase (TEK) could be a potential novel prognostic biomarker for ccRCC. TEK, originally identified as an endothelial cell-specific receptor, plays an important role in the modulation of vasculogenesis and remodeling. Altered TEK expression has been observed in tumor tissues (e.g., oral squamous cell carcinomas, leukemia) and breast, gastric and thyroid cancers. However, the role of TEK in ccRCC remains unknown. PATIENTS AND METHODS: Differential TEK expression between non-metastatic (stage M0) and metastatic (stage M1) ccRCC patient cohorts wa...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Abstract Beta 2-microglobulin (β2m) is a component of the major histocompatibility complex (MHC) class I molecule, which presents tumor antigens to T lymphocytes to trigger cancer cell destruction. Notably, β2m has been reported as persistently expressed, rather than down regulated, in some tumor types. For renal cell and oral squamous cell carcinomas, β2m expression has been linked to increased migratory capabilities. The migratory ability of pancreatic cancer cells contributes to their metastatic tendencies and lethal nature. Therefore, in this study, we examined the impact of β2m on pancreat...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Dongyan Hu, Yu Hu, Jisheng Li, Xiuwen WangJournal of Cancer Research and Therapeutics 2018 14(12):1223-1226 Brain metastasis is synchronous to the diagnosis of renal cell carcinoma (RCC). The prognosis of brain metastasis in RCC with the current treatment options is dismissal. Therefore, we present a case of an elderly female patient with RCC showing a partial response of brain metastasis after 18 months of 600 mg once daily sorafenib treatment who underwent right-sided nephrectomy. Further, withdrawal of sorafenib resulted in psychiatric changes along with increased metastasis lesions, which were recovered upon resuming ...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsDOACs can be safely administered to patients with brain tumors. In patients with primary brain tumors (i.e. glioma), DOACs appear to be safer than LMWH and should be considered for this indication.Figure.DisclosuresZwicker: Incyte: Research Funding; Parexel: Consultancy; Quercegen: Research Funding; Daiichi: Honoraria.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
ConclusionIn patients with malignant intracranial tumors, there is no difference in the risk of ICH or other bleeding events between those on therapeutic anticoagulation with a DOAC or LMWH.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive regulatory T-cell (Treg) expansion, this might suppress antitumor immune responses. Metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs.11/14/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
AbstractBlockade of programmed cell death-1 (PD-1) has become one of the most promising immunotherapies for many human cancers. However, immune-related adverse events can be produced by anti-PD-1 therapy. Uveitis is a rare but potentially devastating side effect of anti-PD-1 therapy. Delay in diagnosis or improper treatment may eventually lead to irreversible blindness. Therefore, it is important for the oncologist and the ophthalmologist to recognize and manage this adverse event properly in patients receiving anti-PD-1 therapy in a timely manner. Here we present a grade 4 panuveitis with bilateral serous retinal detachme...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Odd-skipped related transcription factor 1 (OSR1) suppresses tongue squamous cell carcinoma migration and invasion through inhibiting NF-κB pathway. Eur J Pharmacol. 2018 Sep 19;: Authors: Chen W, Zou A, Zhang H, Fu X, Yao F, Yang A Abstract Tongue squamous cell carcinoma (TSCC) is the most common cancers of oral, owing to the high invasive and metastatic ability, patients with TSCC have poor prognosis, it's important to explore the regulatory mechanism of TSCC invasion and metastasis. Previous studies suggest OSR1 suppresses the progression of gastric cancer and renal cell carcinoma, but its ro...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy. The primary outco...
Source: European Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Research Papers: Urologic Cancer Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Lessons | National Health Service (NHS) | National Institute for Health and Clinical Excelle | National Institutes of Health (NIH) | Oral Cancer | Renal Cell Carcinoma | Science | UK Health | Urology & Nephrology